Key insights
- Radiopharm's RAD 101 showed 90% concordance in a brain metastases trial, potentially improving diagnosis of recurrent disease. The company's stock has faced headwinds recently, but the positive trial data and FDA Fast Track designation could improve investor sentiment. The US market impact is slightly positive due to the potential for improved cancer diagnostics and the company's NASDAQ listing.
SYDNEY - Radiopharm Theranostics (ASX:RAD, NASDAQ:RADX) reported interim results from its Phase 2b clinical trial of RAD 101, an imaging agent for detecting recurrent brain metastases, according to a company press release.
The second interim analysis of 20 patients showed that 90% achieved concordance between PET imaging and MRI, the study’s primary endpoint. RAD 101 is a small-molecule imaging agent targeting fatty acid synthase and radiolabeled with Fluorine-18 for diagnosing suspected recurrent brain metastases from solid tumors.The positive trial data comes as the company’s stock has faced headwinds, declining 31% over the past six months. With a market capitalization of $49 million, the clinical-stage firm maintains a current ratio of 3.01, indicating strong short-term liquidity.
The first five patients with six-month follow-up data and biopsy results showed a positive trend for sensitivity and specificity, which are secondary objectives of the trial. The imaging results demonstrated tumor uptake in brain metastases compared to MRI findings.
The U.S. multicenter, open-label, single-arm trial is evaluating the diagnostic performance of RAD 101 in 30 individuals with confirmed recurrent brain metastases from solid tumors. The study’s primary objective is concordance between RAD 101-positive lesions and those seen in conventional MRI imaging.
RAD 101 has received FDA Fast Track Designation to distinguish between recurrent disease and treatment effects of brain metastases. More than 300,000 patients are diagnosed annually with cerebral metastases in the U.S.
The company expects final data from the full 30-patient study by June 2026. Radiopharm plans to host a webinar on the results today at 6:00 pm EST.
Radiopharm Theranostics is a clinical-stage biopharmaceutical company developing radiopharmaceutical products for diagnostic and therapeutic applications. The company has one Phase 2 and four Phase 1 trials in various solid tumor cancers including lung, breast, and brain metastases.According to InvestingPro analysis, the company holds more cash than debt on its balance sheet, a crucial factor for funding ongoing clinical trials. The platform offers 5 additional ProTips for RAD, along with comprehensive financial health metrics for investors tracking this clinical-stage opportunity.
In other recent news, Radiopharm Theranostics has announced the dosing of the first patient in its phase 1/2a clinical trial for 177Lu-BetaBart, a radiotherapeutic agent. This trial will assess the safety, biodistribution, and radiation dosimetry of the agent, which targets the B7-H3 immune checkpoint molecule. The study plans to enroll 61 participants with various advanced solid tumors, including prostate, colorectal, lung, and breast cancers. Additionally, Radiopharm Theranostics has increased its ownership stake in Radiopharm Ventures from 75% to 87.5%. This joint venture, in collaboration with The University of Texas MD Anderson Cancer Center, focuses on developing radiopharmaceutical cancer treatments, including the lead candidate Betabart. These recent developments highlight Radiopharm’s ongoing efforts in advancing cancer treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.